TY - JOUR T1 - QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA2966 VL - 46 IS - suppl 59 SP - PA2966 AU - Donald Mahler AU - Dorothy Keininger AU - Robert Fogel AU - Karen Mezzi AU - Donald Banerji Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA2966.abstract N2 - Introduction: QVA149 is an approved once-daily dual bronchodilator for maintenance treatment of patients with COPD. Here, we assessed the efficacy of QVA149 in improving dyspnoea, health status and lung function in COPD patients with moderate-to-severe baseline dyspnoea (GOLD Group B) from SHINE and ILLUMINATE studies.Methods: Symptomatic patients from SHINE (N=2144) and ILLUMINATE (N=523) studies with baseline dyspnoea index (BDI) ≤7 (moderate-to-severe dyspnoea equivalent to GOLD Group B) were included in this subgroup analysis. QVA149 was compared to placebo (PBO), open-label tiotropium (TIO), and SFC; TDI, SGRQ and lung function (trough and pre-dose FEV1) were assessed at Week 26.Results: Mean BDI was comparable in both SHINE [QVA149 (n=305): 5.44, TIO (n=313): 5.57, PBO (n=131): 5.47] and ILLUMINATE [QVA149 (n=166): 5.78, SFC (n=179): 5.85] studies. QVA149 provided significant improvement in dyspnoea and lung function, compared with PBO, TIO and SFC (Table). QVA149 also improved (not significant) SGRQ total score versus SFC.View this table:Table: Treatment differences at Week 26Conclusion: In patients with moderate-to-severe baseline dyspnoea (comparable to GOLD Group B), QVA149 was more efficacious than TIO and SFC in improving patient-reported outcomes and lung function. ER -